Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Replimune Group Inc REPL

Healthcare Biotechnology
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:REPL)

Replimune Announces Pricing of Upsized Public Offering

GlobeNewswire 4 hours ago

Replimune Announces Proposed Public Offering

GlobeNewswire 21 hours ago

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

GlobeNewswire 4 days ago

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire 13 days ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

GlobeNewswire November 9, 2024

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 8, 2024

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire October 30, 2024

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 9, 2024

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire October 1, 2024
View More News ››

Opinion & Analysis (NDAQ:REPL)

Coverage Initiated on U.S. Biotech with a 'Potential Best-of-Breed Oncolytic Virus'

Streetwise Reports July 11, 2019
View More Opinion ››

Bullboard Posts (NDAQ:REPL)

Bullish Signals for $MYNZ and $REPL

$MYNZ maintains solid support at 0.20, showing resilience with a bullish MACD crossover—watch for momentum above 0.23. $REPL has broken...
StockHoriz - 18 hours ago

REPL : FDA Fast Track Sparks Price Target Upgrades

$REPL just scored 3 analyst upgrades, with new price targets bumped to $17-18. This is the kind of boost you see when the FDA puts you on...
BullishEdge56 - 3 days ago

$REPL Gains Momentum with Analyst Upgrades and FDA Fast Trac

$REPL received 3 analyst upgrades, all raising their price target to $17-18. That’s what happens when you get into the accelerated FDA...
AlphaTrader1024 - 3 days ago

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical

Breaking News: $REPL Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced MelanomaWOBURN, Mass., Aug. 13, 2024...
whytestocks - August 13, 2024

Replimune Group, Inc. (NASDAQ:REPL): Pioneering Oncolytic Im

http://beyondspx.com/2024/08/02/replimune-group-inc-nasdaqrepl-pioneering-oncolytic-immunotherapies-with-promising-clinical-progress/
MikeTester - August 3, 2024

Replimune Announces $100 Million Private Placement Financing

NEWS: $REPL Replimune Announces $100 Million Private Placement Financing-&#xA0;Led by a life-sciences focused institutional investor...
whytestocks - June 13, 2024
View more Bullboard ››

Calima Energy Ord Shs

Calima Energy Ord Shs

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »